Last reviewed · How we verify
PUL-042
At a glance
| Generic name | PUL-042 |
|---|---|
| Sponsor | Pulmotect, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV) (PHASE2)
- The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2 (PHASE2)
- A Multiple Ascending Dose Study of PUL-042 in Stem Cell Transplant Recipients (PHASE1)
- The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection (PHASE2)
- The Effect of Inhaled PUL-042 on Rhinovirus-induced Symptoms in Smokers With GOLD Stage 0 COPD (PHASE2)
- Effect of Pre-Treatment With Cromolyn or Albuterol on Response to PUL-042 Inhalation Solution (PUL-042) (PHASE1)
- Safety and Tolerability of Single Ascending Doses of PUL-042 Inhalation Solution in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PUL-042 CI brief — competitive landscape report
- PUL-042 updates RSS · CI watch RSS
- Pulmotect, Inc. portfolio CI